<DOC>
	<DOCNO>NCT00937183</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , dendritic cell vaccine make patient 's cancer cell , may stimulate immune system different way stop cancer cell grow . PURPOSE : This phase I/II trial study side effect dendritic cell vaccine see well work treat patient indolent B-cell lymphoma multiple myeloma .</brief_summary>
	<brief_title>Dendritic Cell Vaccine Treating Patients With Indolent B-Cell Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluation feasibility dendritic cell ( DC ) -based vaccination program use autologous tumor cell and/or lysates patient indolent B cell lymphomas multiple myeloma adjuvant therapy induce immune response remission cytoreductive treatment . - Evaluation immune response patient treat regimen . - Evaluation progression-free survival patient treat regimen . - Evaluate adverse event regimen patient . OUTLINE : Patients receive intranodal ( ultrasound guidance ) subcutaneous vaccination adjuvant electrofusion hybrid autologous dendritic cell ( DC ) autologous lymphoma cell , electrofusion hybrid allogeneic DC autologous lymphoma cell , and/or autologous DC pulse autologous tumor lysate cell week 0 , 2 , 4 , 8 , 12 , 18 , 26 , 50 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Mantle cell lymphoma Marginal zone lymphoma Follicular lymphoma Small lymphocytic lymphoma/chronic lymphocytic leukemia Multiple myeloma Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia Diffuse large Bcell lymphoma Adequate sample size lymphoma cell content fresh tissue collect No bulky progressive disease PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month No evidence lung , heart , liver , renal failure severe neurologic disorder No autoimmune disease atopic allergy No HIV positivity No malignancy PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage II marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
</DOC>